NCT03367572 2025-09-25
Treatment of Refractory Nausea and Vomiting in Patients With Breast Cancer
University of Rochester
Phase 3 Completed
Clinical Trials
15 trialsNCT06175273 2025-09-18
POINT
University of Kentucky
Phase 2/3 Completed
NCT03578081 2025-04-06
Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02116530 2025-01-28
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT02939287 2024-10-22
Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan
Rush University Medical Center
Phase 3 Completed
NCT05243251 2024-10-03
Olanzapine Anorexia Cachexia
Cairo University
Phase 3 Completed
NCT04669132 2022-02-23
OLNEPA
Instituto Brasileiro de Controle do Cancer
Phase 2 Completed
NCT03631004 2022-01-13
Pre-operative Olanzapine as Prophylactic Antiemetic in Oncologic Patients
Instituto do Cancer do Estado de São Paulo
Phase 2/3 Completed
NCT03137121 2021-08-17
Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Advanced Cancer Patients
University of Alabama at Birmingham
Phase 2/3 Completed
NCT02861859 2020-02-26
Individualised Versus Standard Care for Breast Cancer Patients at High-risk for Chemotherapy-induced Nausea and Vomiting The ILIAD Study
Ottawa Hospital Research Institute
Phase 3 Completed
NCT02635984 2018-08-20
FOND-O
Augusta University
Phase 3 Completed
NCT00910988 2018-07-18
Healthy Volunteers Study of the Effects of Olanzapine and Ziprasidone
Washington University School of Medicine
Phase NA Completed
NCT01539733 2017-04-07
Early Recognition and Optimal Treatment of Delirium in Patients With Advanced Cancer
Amsterdam UMC, location VUmc
Phase NA Completed
NCT00489593 2015-01-08
Olanzapine in Patients With Advanced Cancer and Weight Loss
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00512291 2011-09-27
Subcutaneous Olanzapine for Hyperactive or Mixed Delirium
M.D. Anderson Cancer Center
Phase NA Completed